Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A local official conducts a check of rabies vaccine doses at a hospital in Rongan, China. Photo: AFP via Getty Images

Changchun Changsheng Biotechnology, a Chinese vaccine manufacturer, gave hundreds of thousands of defective vaccine doses to children as part of mandatory vaccination protocols in China, reports CNN.

The big picture: The Chinese government is walking the line between reforming its health care system and rapidly increasing access to care. "[A]uthorities are understandably keen to open the floodgates in terms of patient access to more affordable treatment," but making sure thousands of local drugmakers are following safety regulations is tough, Sophie Cairns, an Asia-Pacific health care analyst at IHS Markit, tells Axios.

The details:

  • At least 113,000 doses of the company's rabies vaccine are faulty, Chinese state media Xinhua reports.
  • An additional 253,338 doses of diphtheria and tetanus vaccine sold to the Shandong province are defective, per authorities.
  • The doses known to be faulty have been recalled, but it's not yet clear how they will affect the children who already received them.
  • There's a trend here. In November 2017, 400,000 doses of diphtheria and tetanus vaccine produced by the Wuhan Institute of Biological Products were faulty.

The latest:

  • "Those involved will be resolutely punished with zero tolerance," the Chinese government said in a statement. CNN reports that five senior executives of Changchun Changsheng Biotechnology — including the chairwoman — have been taken in for questioning.
  • Chinese Premier Li Keqiang said the company "broke people's moral bottom line."
  • Chinese President Xi Jinping called the issue "vile and shocking" and directed local authorities to "scrape the poison off the bone" as they investigate the incident.
  • Yes, but: "This issue cannot be addressed overnight," says Cairns. It requires the government to recruit and train scores of regulators.

The bottom line: "Accountability beyond local scapegoats is usually lacking in China unless there is a political aspect to the problem. Li Keqiang has been Premier for 64+ months, with oversight of the health system, and he looks particularly ineffective in this case," Axios contributor Bill Bishop writes in his Sinocism newsletter.

Go deeper

The rebellion against Silicon Valley (the place)

Photo illustration: Sarah Grillo/Axios. Smith Collection/Gado via Getty Images

Silicon Valley may be a "state of mind," but it's also very much a real enclave in Northern California. Now, a growing faction of the tech industry is boycotting it.

Why it matters: The Bay Area is facing for the first time the prospect of losing its crown as the top destination for tech workers and startups — which could have an economic impact on the region and force it to reckon with its local issues.

Erica Pandey, author of @Work
1 hour ago - Economy & Business

Telework's tax mess

Illustration: Annelise Capossela/Axios

As teleworkers flit from city to city, they're creating a huge tax mess.

Why it matters: Our tax laws aren't built for telecommuting, and this new way of working could have dire implications for city and state budgets.

Wanted: New media bosses, everywhere

Illustration: Sarah Grillo/Axios

The Washington Post, Los Angeles Times, Reuters, HuffPost and Wired are all looking for new editors. Soon, The New York Times will be too.

Why it matters: The new hires will reflect a new generation — one that's addicted to technology, demands accountability and expects diversity to be a priority.